You are here

Article Text

Article menu
Download PDFPDF
Commentary
General medicine
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism
  1. Lori-Ann Linkins MD, MSc, FRCPC
  1. Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Juravinski Hospital, Room A3-74, Hamilton, Ontario, Canada
  1. Correspondence to Dr Lori-Ann Linkins MD, MSc and FRCPC, Hematology, McMaster University Department of Medicine, Hamilton, Ontario L8S 4K1, Canada; linkinla{at}mcmaster.ca

https://doi.org/10.1136/bmjebm-2018-111007

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378:615–624.

    Context

    Low-molecular-weight heparin (LMWH) is the standard of care for treatment of cancer-associated venous thromboembolism (VTE).1 2 This recommendation is supported largely by a landmark randomised controlled trial (RCT) that showed that patients with cancer who received 6 months of dalteparin instead of warfarin (after an initial 5–7 days of dalteparin) had a 52% risk reduction for recurrent VTE.3 However, LMWH injections can be painful as well as anxiety provoking. A pill would be a welcome alternative for most patients, but only if it is as …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.